GeoVax to Host Conference Call at 4:30 PM ET
ATLANTA, GA - 
(NewMediaWire) - February 22, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing
immunotherapies and vaccines against cancer and infectious diseases, today
announced that it will report 2023 financial results on Thursday, February 29, 2024,
after the close of U.S. markets. Following the release, management will host a live
conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate
update and discuss financial results.
Dial-in numbers:
Domestic: (800) 715-9871
International: +1 (646) 307-1963
Conference ID: 3926207
Webcast:
A webcast of the live call may be accessed here and on the Events page of the GeoVax website. A webcast replay of the call will be available for three months via the same link as the live webcast approximately two hours after the end of the call.
About GeoVax
GeoVax Labs, Inc. is a
clinical-stage biotechnology company developing novel therapies and vaccines
for solid tumor cancers and many of the world’s most threatening infectious
diseases. The company’s lead program in oncology is a novel oncolytic solid tumor
gene-directed therapy, Gedeptin®, presently in a multicenter Phase
1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious
disease candidate is GEO-CM04S1, a next-generation Covid-19 vaccine targeting
high-risk immunocompromised patient populations. Currently in three Phase 2
clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for
immunocompromised patients such as those suffering from hematologic cancers and
other patient populations for whom the current authorized Covid-19 vaccines are
insufficient, and as a booster vaccine in patients with chronic lymphocytic
leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial
evaluating the vaccine as a more robust, durable Covid-19 booster among healthy
patients who previously received the mRNA vaccines. GeoVax has a leadership
team who have driven significant value creation across multiple life science
companies over the past several decades. For more information, visit our website:
www.geovax.com.
| Company Contact: | Investor Relations Contact: | Media Contact: | ||
| info@geovax.com | paige.kelly@sternir.com | sr@roberts-communications.com | ||
| 678-384-7220 | 212-698-8699 | 202-779-0929 |
